Gt biopharma announces ind submission for gtb-3650 for treatment of cd33+ leukemia

Brisbane, california, dec. 04, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced the submission of an investigational new drug (ind) application with the us food and drug administration (fda) for the development of gtb-3650, a 2nd generation nanobody trike® for the treatment of patients with cd33+ leukemia, including relapsed/refractory acute myelogenous leukemia (aml) and high-risk myelodysplastic syndrome (mds).
GTBP Ratings Summary
GTBP Quant Ranking